Implications of Recent Data from CheckMate-142 in CRC


Tanios Bekaii-Saab, MD: At a very high level, we’ve already known that microsatellite instability determines a likelihood of a response to PD-1 inhibitors. We have 2 approvals, pembrolizumab and nivolumab, in this stage. At ASCO GI, we’ve heard updates about nivolumab in MSI-high patients, which seems very consistent with what we’d expect for this group of patients. Those responses occur in 30% to 40% of the patients, and many of the responses can come later. Some of these responses occur beyond 24 weeks, so stable disease can essentially transform into a PR and the PR can transform into a CR.

The other component of the presentation included—it was a separate presentation, but it was part of the same study—nivolumab plus ipilimumab, trying to understand the added benefit of CTLA-4 inhibitors to PD-1 inhibitors. We know that strategy has been looked at in melanoma, has been looked at in gastric cancer, and has been looked at in a number of different cancers. It does seem in colorectal cancer, like with other cancers, to add few more responders historically, at least when compared to a PD-1 inhibitor alone. So, there may be some benefit in doing this, even when we use 2 different doses of nivolumab and 2 different doses of ipilimumab.

The question that remains is, is this going to change the outcome for those patients? In all frankness, in my own clinic, I have patients on the single-agent PD-1 inhibitors who respond tremendously, and they respond for not just a few months but for a few years, and they will never need another agent. The question is, who are those patients who may need the added benefit of CTLA-4 inhibition, and how do we best study this?

At this point in time, I don’t think that these data will change how we practice in clinic. In other words, a patient with an MSI-high tumor remains, at this point of time, a candidate for either pembrolizumab or nivolumab. We have 2 sets of great data with nivolumab presented at ASCO GI. I think the role of ipilimumab in colorectal cancer would need to be explored further and is not yet ready for prime time in clinic.

Transcript Edited for Clarity

Related Videos
Pamela L. Kunz, MD, associate professor, internal medicine (medical oncology), Yale School of Medicine; director, Center for Gastrointestinal (GI) Cancers, chief, GI Medical Oncology, Smilow Cancer Hospital, Yale Cancer Center
Suneel Kamath, MD
Suneel Kamath, MD
Rene Adam, MD, PhD
Jennifer R. Eads, MD, physician lead, GI Cancer Research, director, National Clinical Trials Network, Abramson Cancer Center, University of Pennsylvania, associate professor, clinical medicine (hematology-oncology), Penn Medicine, Perelman Center for Advanced Medicine
Olivia Aranha, MD, PhD
Michael Iglesia, MD, PhD
Petros Grivas, MD, PhD; and Chandler Park, MD, MSc, FACP
Arndt Vogel, MD
Daniel M. Halperin, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center